<DOC>
	<DOC>NCT01588119</DOC>
	<brief_summary>Patients, who are adjusted to a new oral anticoagulant (Dabigatran, Rivaroxaban, Apixaban, Edoxaban) in routine treatment will recorded in this register. Within this register a characterization of patients (with regard to demography and indication) and therapy (with regard to medication, dose and duration) will be done. On basis of defined clinical relevant end points the long-term efficacy and safety will be evaluated.</brief_summary>
	<brief_title>Register for New Oral Anticoagulants</brief_title>
	<detailed_description />
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>indication for treatment with long term anticoagulation initial adjustment or change to nex oral anticoagulant within routine treatment indication for treatment with long term anticoagulation within the register: permanent anticoagulation in arterial fibrillation intended anticoagulation in acute venous thromboembolism for min. 3 months other anticoagulation for min. 3 months within the approved indication missing Informed Consent Form missing phone number for telephone follow up contraindication for therapy with new oral anticoagulant (Dabigatran, Rivaroxaban, Apixaban, Edoxaban) according to Summary of Product Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>